Preclinical Development of a vaccine for HTLV-1

January 2019December 2026

Project summary

Human T-lymphotropic virus type-1 (HTLV-1) is a cause of T-cell leukemia/lymphoma as well as severe autoimmune disorders. An estimated 5-10 million individuals are infected globally, with Indigenous populations in central Australia most highly affected. Using the second-generation molecular Clamp platform, we seek to develop a candidate HTLV-1 glycoprotein vaccine using the Molecular Clamp and utilise this antigen to discover neutralising monoclonal antibodies as potential therapeutic agents.


Chimeric molecules and uses thereof

Key publications

Coming soon…

Project members

Professor Keith Chappell

Group Leader
Chappell Group

Dr Jake O’Donnell

Research Fellow
Chappell Group

Dr Noushin Jaberolansar

Research Fellow
Chappell group